Blockchain Registration Transaction Record

Helus Pharma's Phase 3 Trial for Depression Drug Hits 86% Enrollment

Helus Pharma announces Phase 3 APPROACH trial for HLP003, a novel serotonergic agonist for major depressive disorder, surpasses 86% enrollment. Breakthrough Therapy Designation supports potential new depression treatment.

This milestone matters because major depressive disorder affects over 280 million people globally, and many patients do not respond adequately to existing treatments. Helus Pharma's HLP003, with its Breakthrough Therapy Designation, could offer a novel mechanism of action by promoting neuroplasticity through serotonin pathway activation. If successful, this drug could provide a new, effective option for treatment-resistant depression, potentially improving outcomes for millions. The progress of the APPROACH trial brings us closer to a new class of antidepressants that may offer durable relief, addressing a significant unmet medical need.